Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADIGM: Panitumumab vs Bevacizumab in mCRC
NCT02394795Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2015
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of panitumumab in colorectal cancer (CRC), sponsored by Takeda. Started May 2015; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02394795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394795.